Literature DB >> 15196742

Severe myelotoxicity in a combination of gefitinib and vinorelbine.

Mana Yoshimura, Shinichiro Nakamura, Fumio Imamura, Kiyonobu Ueno, Suguru Yamamoto, Tsuyoshi Igarashi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15196742     DOI： 10.1016/j.lungcan.2004.01.006

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  4 in total

1.  Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines.

Authors:  Kaisa Erjala; Misa Raitanen; Jarmo Kulmala; Reidar Grénman
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-05       Impact factor: 4.553

2.  Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib.

Authors:  Brian J Trummer; Vandana Iyer; Sathy V Balu-Iyer; Robert O'Connor; Robert M Straubinger
Journal:  J Pharm Sci       Date:  2012-05-11       Impact factor: 3.534

3.  Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study.

Authors:  Seigo Minami; Takashi Kijima; Ryo Takahashi; Hiroshi Kida; Takeshi Nakatani; Masanari Hamaguchi; Yoshiko Takeuchi; Izumi Nagatomo; Suguru Yamamoto; Isao Tachibana; Kiyoshi Komuta; Ichiro Kawase
Journal:  BMC Cancer       Date:  2012-07-18       Impact factor: 4.430

4.  Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?

Authors:  Young Hak Kim; Akiko Fukuhara; Michiaki Mishima
Journal:  Case Rep Oncol       Date:  2011-09-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.